Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Specialty Channel

Chronic Lymphocytic Leukemia
Specialty Channel
Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
03/25/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated...
03/25/2024
Oncology
News
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL
03/15/2024

Amber Denham

Amber Denham
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up...
03/15/2024
Oncology
News
Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL
02/05/2024
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved...
02/05/2024
Oncology
News
MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy
02/05/2024
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual...
02/05/2024
Oncology
News
CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL
01/24/2024
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved...
01/24/2024
Oncology
Adrian Wiestner, MD
Conference Coverage
Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment
01/12/2024
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
News
Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL
11/20/2023
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results...
11/20/2023
Oncology

News

Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
03/25/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated...
03/25/2024
Oncology
News
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL
03/15/2024

Amber Denham

Amber Denham
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up...
03/15/2024
Oncology
News
Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL
02/05/2024
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved...
02/05/2024
Oncology
News
MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy
02/05/2024
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual...
02/05/2024
Oncology
News
CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL
01/24/2024
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved...
01/24/2024
Oncology
Adrian Wiestner, MD
Conference Coverage
Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment
01/12/2024
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.
At the 65th ASH Annual Meeting,...
01/12/2024
Oncology
News
Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL
11/20/2023
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results...
11/20/2023
Oncology
News
Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA
09/21/2023
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that...
09/21/2023
Oncology

Interactive Features

Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Adding Venetoclax to High-Risk Chronic Lymphocytic Leukemia Treatment
10/31/2023
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax...
10/31/2023
Oncology
Quiz
Venetoclax for CLL With High-Risk Features
10/05/2023
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax...
10/05/2023
Oncology
Quiz
Ibrutinib Plus Venetoclax Combination for Previously Untreated CLL
09/01/2023
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the...
09/01/2023
Oncology
Quiz
FDA Approval of Zanubrutinib for CLL/SLL
05/23/2023
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib...
05/23/2023
Oncology
Quiz
Quiz: Overall Survival Rate of Venetoclax Plus Rituximab Treatment in Patients With Relapsed/Refractory CLL
12/01/2022
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival...
12/01/2022
Oncology
Quiz
Quiz: Obinutuzumab in Patients With Chronic Lymphocytic Leukemia That Responded to Chemo-Immunotherapy
12/01/2022
True or false: Obinutuzumab is well-tolerated in patients with chronic lymphocytic leukemia that responded to chemo-immunotherapy, according to a phase 2/3 trial.
True or false: Obinutuzumab is well-tolerated in patients with chronic lymphocytic leukemia that responded to chemo-immunotherapy, according to a phase 2/3 trial.
True or false: Obinutuzumab is...
12/01/2022
Oncology
Quiz
Quiz: Zanubrutinib as Frontline Therapy for CLL and SLL
10/12/2022
True or False: Zanubrutinib significantly improved progression-free survival vs bendamustine–rituximab as a frontline therapy for CLL and SLL.
True or False: Zanubrutinib significantly improved progression-free survival vs bendamustine–rituximab as a frontline therapy for CLL and SLL.
True or False: Zanubrutinib...
10/12/2022
Oncology
Quiz
Quiz: MRD-Guided, Time-Limited Treatment With Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL
09/05/2022
True or false: MRD-guided, time-limited treatment with ibrutinib plus venetoclax may be beneficial for patients with relapsed/refractory CLL, according to a phase 2 trial.
True or false: MRD-guided, time-limited treatment with ibrutinib plus venetoclax may be beneficial for patients with relapsed/refractory CLL, according to a phase 2 trial.
True or false: MRD-guided,...
09/05/2022
Oncology

Recent News

News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
03/25/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...
The FDA granted accelerated...
03/25/2024
Oncology
News
Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL
03/15/2024

Amber Denham

Amber Denham
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...
According to 5-year follow-up...
03/15/2024
Oncology
News
Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL
02/05/2024
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.
Venetoclax-obinutuzumab achieved...
02/05/2024
Oncology
News
MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy
02/05/2024
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...
Measurable residual...
02/05/2024
Oncology
News
CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL
01/24/2024
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.
CD19 CAR T-cell therapy achieved...
01/24/2024
Oncology
News
Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL
11/20/2023
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 1/2 trial results...
11/20/2023
Oncology
News
Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA
09/21/2023
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.
A phase 2 trial found that...
09/21/2023
Oncology
News
Venetoclax Consolidation Therapy Increased Achievement of Undetectable MRD Among Patients With High-Risk CLL
09/18/2023
The addition of venetoclax to ibrutinib treatment among patients with high-risk chronic lymphocytic leukemia achieved a high rate of undetectable measurable residual disease in the bone marrow.
The addition of venetoclax to ibrutinib treatment among patients with high-risk chronic lymphocytic leukemia achieved a high rate of undetectable measurable residual disease in the bone marrow.
The addition of venetoclax to...
09/18/2023
Oncology
News
T-Lymphocyte Subgroups at Diagnosis Demonstrate Prognostic Value for Patients With Chronic Lymphocytic Leukemia
09/08/2023
Low T-lymphocyte percentages and low T-lymphocyte/MBC ratios at diagnosis were associated with poor prognosis, progressive disease, and decreased survival among patients with previously untreated CLL, according to findings presented at the...
Low T-lymphocyte percentages and low T-lymphocyte/MBC ratios at diagnosis were associated with poor prognosis, progressive disease, and decreased survival among patients with previously untreated CLL, according to findings presented at the...
Low T-lymphocyte percentages and...
09/08/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use